Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Drs Chunxiao Song and Benjamin Schuster-Böckler publish their highly sensitive detection technology that could enable a new blood-based early detection cancer test.

For cancer earlier detection, researchers are seeking to develop methodologies that are less invasive than current diagnostic tests, which would allow them to be performed on more people and at a higher frequency. Liquid biopsies, taking advantage of cancer-specific biomarkers such as tumour-derived DNA in the blood, urine or saliva, are an attractive opportunity for a minimally invasive diagnostic assay.   

Methylation and hydroxymethylation of cytosine (5mC and 5hmC) are chemical epigenetic modifications of DNA that are associated with changes in gene expression. Levels of 5mC and 5hmC are altered in cancer and so detection of methylation on circulating tumour DNA within blood samples could form the basis of a blood-based cancer test. However, up until now, the main method for detecting these modifications relied on harsh bisulphite treatment, making it challenging to measure levels in samples with low amounts of DNA such as liquid biopsies. In this paper published in Nature Biotechnology, OxCODE researchers from Chunxiao Song’s and Benjamin Schuster-Böckler’s groups at the Ludwig Institute for Cancer Research develop TAPS (TET-assisted pyridine borane sequencing), a novel bisulphite-free, base resolution and highly sensitive method for measuring 5mC and 5hmC, in addition to detecting DNA mutations and copy number variations.

For more information, see the Ludwig Cancer Research press release and the Nature Biotechnology "Behind the Paper" blog.

Research in Chunxiao Song's and Benjamin Schuster-Böckler's labs is funded by:

Ludwig Cancer Research logoNIHR Oxford Biomedical Research Centre logoCancer Research UK logoHilton Foundation logo

 

Similar stories

Funded DPhil studentships in early detection available - apply now for October 2023 entry

Oxford research groups are recruiting DPhil candidates for the funded DPhil in Cancer Science commencing in October 2023.

First DeLIVER study day

On Wednesday 8th June 2022, the DeLIVER consortium gathered for the first time to hear about the team’s progress towards the aim of detecting liver cancer earlier.